Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R43/R44 - Clinical Trials Optional)
ID: 356956Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/356956

Additional Information

http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-018.html
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods," aimed at small businesses. This initiative seeks to develop innovative, cost-effective drug detection technologies capable of identifying both known and emerging drugs, such as xylazine and nitazenes, with sensitivity comparable to liquid chromatography-mass spectrometry (LC-MS). The program emphasizes the need for user-friendly devices that can facilitate on-site drug detection, thereby addressing public health challenges related to drug misuse. A total budget of approximately $3 million is available for four to seven grants, with applications due by January 19, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity's webpage at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-018.html.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    RFA-DA-26-018-Full-Announcement.html
    RFA-DA-26-018.html
    The National Institutes of Health (NIH), specifically the National Institute on Drug Abuse (NIDA), has published a funding opportunity aimed at developing cost-effective, user-friendly drug detection technologies. The program, titled "Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods," invites small businesses to create devices that identify both known and unknown drugs with sensitivity comparable to that of liquid chromatography-mass spectrometry (LC-MS). Key goals include reducing overall costs and minimizing the complexity of testing to facilitate on-site drug detection, particularly for emerging drugs like xylazine and nitazenes. The funding structure allows for various grant types, including Phase I, Phase II, and Fast Track options, with a total budget of approximately $3 million available for four to seven grants. Eligible applicants are U.S.-based small business concerns, which must meet specific regulatory criteria. The notice emphasizes the importance of innovative approaches and the necessity for comprehensive commercialization plans, particularly regarding market readiness and potential revenue generation. The deadline for applications is set for January 19, 2025, underlining the urgency of addressing the growing issues surrounding drug misuse and detection capabilities in public health settings.
    Similar Opportunities
    Addressing Challenges in Detecting New Drugs: Instrumentation for Alternative Analytical Methods (R41/R42 - Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Small Business Technology Transfer (STTR) Grant, specifically under the R41/R42 program, aimed at developing innovative devices for the detection of new and existing drugs. This funding opportunity encourages small businesses to create cost-effective, user-friendly technologies that can detect drugs at the point-of-need, such as in emergency departments or harm reduction centers, utilizing target-agnostic methods that provide greater sensitivity and selectivity than traditional detection methods. With a total funding amount of $3 million available to support approximately four to seven projects, applications are due by February 19, 2025, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries or visit the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-26-019.html.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R43/R44 - Clinical Trial Optional)" aimed at supporting Small Business Innovation Research (SBIR) proposals. This initiative seeks innovative, accessible, and affordable solutions to address health complications arising from non-disordered drug use, including issues such as hypoxia-related brain injuries from opioid overdoses and cardiovascular problems from stimulant use. The program anticipates a total budget of $2 million for approximately 2-5 awards in Fiscal Year 2025, with applications due by December 2, 2024. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Solutions to enable diagnosis and treatment of adverse health consequences of non-disordered drug use (R41/R42 - Clinical Trial Optional)." This initiative aims to support Small Business Technology Transfer (STTR) grant applications focused on developing innovative and accessible solutions to improve health outcomes for individuals affected by non-disordered drug use. The program emphasizes the creation of affordable interventions that can be implemented in community-based care systems, targeting vulnerable populations with limited access to traditional healthcare services. Funding amounts of up to $400,000 for Phase I and $3 million for Phase II are available, with applications due by December 3, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R41/R42 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)." This initiative invites Small Business Technology Transfer (STTR) grant applications from small business concerns proposing research projects aimed at developing innovative, FDA-regulated medical products to address the urgent needs of patients suffering from opioid and stimulant use disorders. The program is particularly focused on two scientific areas: pharmacotherapeutics and medical therapeutic and diagnostic devices, including software as a medical device, in response to the national crisis of substance use disorders. Grants of up to $300,000 are available, with a submission deadline of February 14, 2025, and interested applicants can find more information by contacting NIH Grants Information at grantsinfo@nih.gov or visiting the official announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-038.html.
    Development of Medications to Prevent and Treat Opioid and/or Stimulant Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity aimed at the development of medications to prevent and treat opioid and stimulant use disorders and overdose. This initiative seeks innovative preclinical and clinical research projects that can lead to FDA-approved therapies, focusing on areas such as prevention of substance use initiation, treatment adherence, and reduction of overdose risks. With a maximum funding amount of $3 million per year over a project period of five years, applicants are encouraged to submit proposals that demonstrate their capability to manage the research effectively, adhering to detailed application instructions. Interested parties can find more information and application details at the NIH grants website, with the application deadline set for September 1, 2025.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanism for Time-Sensitive Substance Use Research" under the National Institute on Drug Abuse (NIDA). This grant, designated as R21, aims to support pilot, feasibility, and exploratory research addressing urgent issues in substance use epidemiology and health services, particularly in response to sudden increases in substance misuse and emerging public health challenges. Eligible applicants include a wide range of entities such as educational institutions, governmental bodies, and nonprofit organizations, with a budget cap of $275,000 over two years. Interested parties must submit their applications by September 9, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research," aimed at supporting urgent exploratory research in substance use epidemiology and health services. This funding initiative focuses on five priority areas, including responses to sudden spikes in drug use, emerging marijuana trends, and time-sensitive issues related to prescription drug abuse and addiction services within the evolving healthcare system. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and state or local governments, with funding available up to $275,000 over a two-year period. Interested parties should note that the application deadline is January 14, 2025, and are encouraged to consult with NIH contacts for alignment with the FOA’s priorities. For further details, applicants can refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD) (R43/R44 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for Small Business Innovation Research (SBIR) grants aimed at developing regulated therapeutic and diagnostic solutions for patients affected by Opioid Use Disorders (OUD) and Stimulant Use Disorders (StUD). This initiative encourages small businesses to propose research projects focused on the commercialization of novel, FDA-regulated medical products, specifically in the areas of pharmacotherapeutics and medical therapeutic and diagnostic devices, including software solutions. Given the urgent public health crisis highlighted by rising drug overdose fatalities, this funding aims to enhance treatment accessibility and efficacy for affected individuals and communities. Interested applicants can apply for a total funding amount of approximately $3 million, with a submission deadline of February 14, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-23-021.html.
    Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional)" aimed at innovative analyses of existing datasets related to substance use behaviors and disorders. This initiative seeks to enhance understanding of the etiology and epidemiology of drug use, prevention strategies, and health service utilization by leveraging already available social science, neuroimaging, and administrative data, excluding primary data collection. The funding, with an anticipated commitment of $2 million for 3-5 awards, emphasizes compliance with ethical research practices and is open to a wide range of eligible applicants, including educational institutions and nonprofit organizations. Applications are due by November 15, 2024, and further details can be found at the provided link or by contacting the NIH OER Webmaster at OERWebmaster03@od.nih.gov.